Taken together, these results suggest that functional oncogene signatures can accurately predict drug sensitivity and specifically support a role for BCL2L1 as a novel driver oncogene and potential therapeutic target in a subset of breast cancers. This evidence concerns the gene BCL2L1 and breast carcinoma.